News Releases

June 17, 2021
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
CAMBRIDGE, Mass. , June 17, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel...
June 15, 2021
Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
- SYNB1618 Phase 2 study in patients with PKU ongoing with readout expected in 2H 2021; SYNB1934 demonstrates 2-fold improvement in activity in multiple pre-clinical models - - SYNB8802 Phase 1 study ongoing; readout from Part B placebo-controlled crossover in patients with Enteric Hyperoxaluria...
June 10, 2021
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting
- SYNB8802 Phase 1 study in patients with Enteric Hyperoxaluria ongoing; readout from Part B placebo-controlled crossover stage expected 2H 2021 -   Cambridge, Mass. (PR Newswire) June 10, 2021 – Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of...
June 3, 2021
Synlogic Reminds Stockholders of 2021 Annual General Meeting Details
CAMBRIDGE, Mass. , June 3, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on June 10, 2021 at 9:00 am ET ....
May 25, 2021
Synlogic to Present at Upcoming Virtual Banking and Industry Conference
CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
May 23, 2021
Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass. , May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of...
May 13, 2021
Synlogic Reports First Quarter Financial Results and Provides Business Update
- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension...
May 6, 2021
Synlogic Announces First Quarter 2021 Conference Call & Webcast
CAMBRIDGE, Mass. , May 6, 2021 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its first quarter 2021 financial results before the market opens on Thursday,...
April 16, 2021
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , April 16, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering...
April 15, 2021
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. , April 15, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....
April 13, 2021
Synlogic Presents Data Demonstrating Activity of a Solid Oral Formulation of SYNB1618 at American College of Medical Genetics (ACMG) Annual Meeting
- SYNB1618 demonstrates proof of mechanism and phenylalanine (Phe) consumption in GI tract of healthy volunteers - - SYNB1618 Phase 2 study in patients with PKU ongoing - CAMBRIDGE, Mass. , April 13, 2021   Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative...
April 10, 2021
Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
- Data demonstrates activation of STING pathway in patients - - Combination arm of Phase 1 study of SYNB1891 ongoing - CAMBRIDGE, Mass. , April 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine,...
Displaying 13 - 24 of 156